<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Heart failure in patients with reduced ejection fraction: HFSA 2010 comprehensive heart failure practice guideline.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Heart Failure Society of America, Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA, Givertz MM, Katz SD, Klapholz M, Moser DK, Rogers JG, Starling RC, Stevenson WG, Tang WH, Teerlink JR, Walsh MN. Heart failure in patients with reduced ejection fraction: HFSA 2010 comprehensive heart failure practice guideline. J Card Fail. 2010 Jun;16(6):e73-97. [174 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: Heart Failure Society of America. Heart failure in patients with left ventricular systolic dysfunction. J Card Fail 2006 Feb;12(1):e38-57.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Congestive heart failure, unspecified  (428.0); Heart failure, unspecified  (428.9)"/><FieldValue Value="MSH: Adrenergic beta-Antagonists ; Amiodarone ; Angiotensin II Type 1 Receptor Blockers ; Angiotensin-Converting Enzyme Inhibitors ; Anticoagulants ; Digoxin ; Diuretics ; Drug Therapy, Combination ; Fatty Acids, Unsaturated ; Heart Failure ; Hydralazine ; Nitrates ; Platelet Aggregation Inhibitors ; Polypharmacy ; Ventricular Dysfunction, Left "/><FieldValue Value="MTH: Adrenergic beta-Antagonists ; Aldosterone Antagonists ; Angiotensin II Type 1 Receptor Blockers ; Angiotensin-Converting Enzyme Inhibitors ; Anticoagulants ; Combination Drug Therapy ; Congestive heart failure ; Digoxin ; Heart failure ; Measurement of Left Ventricular Ejection Fraction ; Nitrates ; Platelet Aggregation Inhibitors ; Polypharmacy (finding) "/><FieldValue Value="PDQ: digoxin "/><FieldValue Value="SNOMEDCT_US: Aldosterone antagonist  (346312000); Aldosterone antagonist  (372603003); Amiodarone  (372821002); Amiodarone  (69236009); Angiotensin-converting enzyme inhibitor agent  (372733002); Angiotensin-converting enzyme inhibitor agent  (41549009); Anticoagulant  (372862008); Anticoagulant  (81839001); beta-Blocking agent  (33252009); beta-Blocking agent  (373254001); Cardiac ejection fraction  (70822001); Congestive heart failure  (42343007); Digoxin  (387461009); Digoxin  (796001); Diuretic  (30492008); Diuretic  (372695000); Heart failure  (84114007); Hydralazine  (22696000); Hydralazine  (387125005); Nitrate salt  (89119000); Polypharmacy  (129846003); Polyunsaturated fatty acid supplementation  (226298006); Unsaturated fatty acid  (21625008)"/></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Heart failure with reduced left ventricular ejection fraction (LVEF)&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;strong&gt;Note&lt;/strong&gt;: Heart failure is a syndrome caused by cardiac dysfunction, generally resulting from myocardial muscle dysfunction or loss and characterized by either left ventricular (LV) dilation or hypertrophy or both.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Prevention" /><FieldValue Value="Treatment" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Cardiology" /><FieldValue Value="Family Practice" /><FieldValue Value="Internal Medicine" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Advanced Practice Nurses" /><FieldValue Value="Pharmacists" /><FieldValue Value="Physician Assistants" /><FieldValue Value="Physicians" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;To provide recommendations for the treatment of heart failure in patients with reduced ejection fraction &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To update and expand the previous 2006 clinical practice guidelines &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Patients with heart failure patients&amp;nbsp;and reduced ejection fraction&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Angiotensin-converting enzyme (ACE) inhibitors &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Angiotensin receptor blockers (ARBs) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Oral nitrates and hydralazine &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Beta blockers (alone and in combination of ACE inhibitors)&lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Aldosterone antagonists &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Multi-drug therapy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Diuretic therapy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Digoxin &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Anticoagulation and antiplatelet drugs &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Amiodarone therapy&lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Polyunsaturated fatty acids&lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Signs and symptoms &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Quality of life &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Progression of cardiac and peripheral dysfunction &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Side effects of therapy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Mortality and morbidity&lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A literature search with relevant key words and phrases for each guideline section were provided to members of the subcommittees and the full Guideline Committee. Members of each subcommittee were asked to review the search and identify any additional relevant medical evidence for each assigned section.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The following databases were searched:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Ovid Medline (1950 to the updated date when the search was conducted) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Ovid Medline In-Process and other Non-Indexed Citations &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;PubMed &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;The searches focused primarily on the period between the last guideline publication and current, although the authors went back to 2005 to account for publication lag between the completion of the guideline and its publication in 2006 (i.e., 2005&amp;ndash;2010) in the event there was some information that should/could be added to the 2010 updated document. Generally only non-human studies and publications that were non-English were excluded.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The following search terms were used: Heart failure; ventricular dysfunction, left; angiotensin-converting enzyme inhibitors; angiotensin II type 1 receptor blockers; adrenergic beta-antagonists; aldosterone antagonists; nitrates; hydralazine; diuretics; digoxin; anticoagulants; platelet aggregation inhibitors; atrial fibrillation; arrhythmias, cardiac; fatty acids, unsaturated; amiodarone; defibrillators, implantable; cardiac resynchronization (as a keyword); biventricular pacemaker (as a keyword).&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Expert Consensus" /><FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: Hierarchy of Types of Evidence&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; colspan=&quot;2&quot;&gt;Hierarchy of Types of Evidence&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Level A&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Randomized, Controlled, Clinical Trials&lt;br /&gt;&#xD;&#xA;            May be assigned based on results of a single methodologically rigorous trial&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Level B&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Cohort and Case-Control Studies&lt;br /&gt;&#xD;&#xA;            Post hoc, subgroup analysis, and meta-analysis&lt;br /&gt;&#xD;&#xA;            Prospective observational studies or registries&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Level C&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Expert Opinion&lt;br /&gt;&#xD;&#xA;            Observational studies &amp;ndash; epidemiologic findings&lt;br /&gt;&#xD;&#xA;            Safety reporting from large-scale use in practice&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Review of Published Meta-Analyses" /><FieldValue Value="Systematic Review" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Heart Failure Society of America (HFSA) Guideline Approach to Medical Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Two considerations are critical in the development of practice guidelines: assessing strength of evidence and determining strength of recommendation. Strength of evidence is determined both by the type of evidence available and the assessment of validity, applicability, and certainty of a specific type of evidence. Following the lead of previous guidelines, strength of evidence in this guideline is heavily dependent on the source or type of evidence used. The HFSA guideline process has used three grades (A, B, or C) to characterize the type of evidence available to support specific recommendations (see Table 1.2 in the original guideline document).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;HFSA Guideline Approach to Strength of Recommendation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Determining Strength. Although level of evidence is important, the strength given to specific recommendations is critical. The process used to determine the strength of individual recommendations is complex. The goal of guideline development is to achieve the best recommendations for evaluation and management, considering not only efficacy, but the cost, convenience, side effect profile, and safety of various therapeutic approaches. The HFSA guideline committee often determined the strength of a recommendation by the &quot;totality of evidence,&quot; which is a synthesis of all types of available data, pro and con, about a particular therapeutic option. The HFSA guideline employs the categorization for strength of recommendation outlined in Table 1.3 in the original guideline document.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Process of Guideline Development&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Key steps in the development of this guideline are listed in Table 1.4 in the original guideline document. Having determined the broad scope of the current guideline, subcommittees of the guideline committee were formed for each section of the guideline. A literature search with relevant key words and phrases for each guideline section were provided to members of the subcommittees and the full Guideline Committee. Members of each subcommittee were asked to review the search and identify any additional relevant medical evidence for each assigned section. Changes in recommendation and background were carried out by each subcommittee with conference calls directed by the Guideline Committee chair. Each section was presented for comments and consensus approval to the Guideline Committee. Once subsections were complete, the Executive Council reviewed and commented on each section and these comments were returned to the Guideline Committee for changes and once complete, for final approval by the Executive Council.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Consensus&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Heart Failure Society of America (HFSA) Guideline Committee sought resolution of difficult cases through consensus building. An open, dynamic discussion meant that no single voice was allowed to dominate. Written documents were essential to this process, because they provided the opportunity for feedback from all members of the group. On occasion, consensus of opinion was sufficient to override positive or negative results of almost any form of evidence. The HFSA process had a strong commitment to recommendations based on objective evidence rigorously reviewed by a panel of experts. Issues that caused difficulty for the HFSA guideline process were some of the more important ones faced by the committee, because they mirrored those that are often most challenging to clinicians in day-to-day practice. The foundation of the HFSA guideline process was the belief&amp;nbsp;that the careful judgment of recognized opinion leaders in these controversial areas is more likely to be correct than ad hoc decisions made &quot;on the spot&quot; by physicians in practice.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Classifying the Strength of the Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: Classifying the Strength of the Recommendations&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&quot;Is recommended&quot;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Part of routine care&lt;br /&gt;&#xD;&#xA;            Exceptions to therapy should be minimized. &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&quot;Should be considered&quot;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Majority of patients should receive the intervention.&lt;br /&gt;&#xD;&#xA;            Some discretion in application to individual patients should be allowed.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&quot;May be considered&quot; &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Individualization of therapy is indicated.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&quot;Is not recommended&quot;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Therapeutic intervention should not be used&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Data from a decision analysis/cost-effectiveness modeling study suggested that prophylactic pacemaker insertion to allow beta blocker treatment in patients with bradycardia may be associated with clinical benefits, and may be cost-effective.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="Internal Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Each section was presented for comments and consensus approval to the Guideline Committee. Once subsections were complete, the Executive Council reviewed and commented on each section and these comments were returned to the Guideline Committee for changes and once complete, for final approval by the Executive Council.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The strength of evidence (A, B, C) and strength of recommendations are defined at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Angiotensin-converting Enzyme (ACE) Inhibitors&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;ACE inhibitors are recommended for routine administration to symptomatic and asymptomatic patients with left ventricular ejection fraction (LVEF) &amp;le;40%. (Strength of Evidence = A) ACE inhibitors should be titrated to doses used in clinical trials, as tolerated during concomitant up-titration of beta-blockers. (Strength of Evidence = C). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;It is recommended that other therapy be substituted for ACE inhibitors in the following circumstances:&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;In patients who cannot tolerate ACE inhibitors due to cough, angiotensin receptor blockers (ARBs) are recommended. (Strength of Evidence = A) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;The combination of hydralazine and an oral nitrate may be considered in such patients not tolerating ARB therapy. (Strength of Evidence = C) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Patients intolerant to ACE inhibitors from hyperkalemia or renal insufficiency are likely to experience the same side effects with ARBs. In these cases, the combination of hydralazine and an oral nitrate should be considered. (Strength of Evidence = C) &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;ARBs are recommended for routine administration to symptomatic and asymptomatic patients with a left ventricular ejection fraction (LVEF) &amp;le;40% who are intolerant to ACE inhibitors for reasons other than hyperkalemia or renal insufficiency. (Strength of Evidence = A) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;ARBs should be considered in patients experiencing angioedema while on ACE inhibitors based on their underlying risk and with recognition that angioedema has been reported infrequently with ARBs. (Strength of Evidence = B) The combination of hydralazine and oral nitrates may be considered in this setting in patients who do not tolerate ARB therapy. (Strength of Evidence = C) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Individual ARBs may be considered as initial therapy rather than ACE inhibitors for patients with the following conditions:&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Heart failure (HF) post-myocardial infarction (MI) (Strength of Evidence = A) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Chronic HF and reduced LVEF (Strength of Evidence = B) &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Beta Adrenergic Receptor Blockers&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Table. Summary of Recommendations for the Administration of Beta Blocker Therapy&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: Summary of Recommendations for the Administration of Beta-Blocker Therapy&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;General&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Initiate at low doses. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Uptitrate gradually, generally no sooner than at 2-week intervals. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Use target doses shown to be effective in clinical trials. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Aim to achieve target dose in 8 to 12 weeks. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Maintain at maximum tolerated dose. &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Considerations if symptoms worsen or other side effects appear&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Adjust dose of diuretic or other concomitant vasoactive medication. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Continue titration to target dose after symptoms return to baseline. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Considerations if uptitration continues to be difficult&#xD;&#xA;                &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                    &lt;li&gt;Prolong titration interval &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Reduce target dose &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Consider referral to a HF specialist &lt;/li&gt;&#xD;&#xA;                &lt;/ul&gt;&#xD;&#xA;                &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;If an acute exacerbation of chronic HF occurs&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Maintain therapy if possible. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Reduce dosage if necessary. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Avoid abrupt discontinuation. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;If discontinued or reduced, reinstate gradually before discharge. &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;6&quot;&gt;&#xD;&#xA;    &lt;li&gt;Beta-blockers shown to be effective in clinical trials of patients with HF are recommended for patients with an LVEF &amp;le;40%. (Strength of Evidence = A) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The combination of a beta blocker and an ACE inhibitor is recommended as routine therapy for asymptomatic patients with a LVEF &amp;le;40%&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Post-myocardial infarction (MI) (Strength of Evidence = B) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Non Post-MI (Strength of Evidence = C) &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Beta blocker therapy is recommended for patients with a recent decompensation of HF after optimization of volume status and successful discontinuation of intravenous diuretics and vasoactive agents, including inotropic support. Whenever possible, beta blocker therapy should be initiated in the hospital setting at a low dose prior to discharge in stable patients. (Strength of Evidence = B) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Beta blocker therapy is recommended in the great majority of patients with HF and reduced LVEF, even if there is concomitant diabetes, chronic obstructive lung disease, or peripheral vascular disease. Beta blocker therapy should be used with caution in patients with diabetes with recurrent hypoglycemia, with asthma, or with resting limb ischemia. Considerable caution should be used if beta blockers are initiated in patients with marked bradycardia (&amp;lt;55 beats/min) or marked hypotension (systolic blood pressure &amp;lt;80 mm Hg). Beta blockers are not recommended in patients with asthma with active bronchospasm. (Strength of Evidence = C) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;It is recommended that beta blockade be initiated at low doses and uptitrated gradually, typically at 2-week intervals in patients with reduced LVEF, and after 3 to 10 day intervals in patients with reduced LVEF following newly diagnosed MI. (Strength of Evidence = B) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;It is recommended that beta blocker therapy be continued in most patients experiencing a symptomatic exacerbation of HF during chronic maintenance treatment, unless they develop cardiogenic shock, refractory volume overload, or symptomatic bradycardia. (Strength of Evidence = C) A temporary reduction of dose (generally by one half) in this setting may be considered. Abrupt discontinuation in patients with symptomatic exacerbation should be avoided, unless the situation is life-threatening. (Strength of Evidence = C) If discontinued or reduced, beta blockers should be reinstated before the patient is discharged. In general, doses should be uptitrated to the previous well-tolerated dose as soon as safely possible. (Strength of Evidence = B) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Angiotensin Receptor Blockers (ARBs)&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;12&quot;&gt;&#xD;&#xA;    &lt;li&gt;The routine administration of an ARB is not&amp;nbsp;recommended in addition to ACE inhibitor and beta blocker therapy in patients with a recent acute MI and reduced LVEF. (Strength of Evidence = A) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The addition of an ARB should be considered in patients with HF due to reduced LVEF who have persistent symptoms or progressive worsening despite optimized therapy with an ACE inhibitor and beta blocker. (Strength of Evidence = A) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Aldosterone Antagonists&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;14&quot;&gt;&#xD;&#xA;    &lt;li&gt;Administration of an aldosterone antagonist is recommended for patients with New York Heart Association (NYHA) class IV (or class III, previously class IV) HF from reduced LVEF (&amp;le;35%) while receiving standard therapy, including diuretics. (Strength of Evidence = A) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Administration of an aldosterone antagonist should be considered in patients following an acute MI, with clinical HF signs and symptoms or history of diabetes mellitus, and an LVEF &amp;lt;40%. Patients should be on standard therapy, including an ACE inhibitor (or ARB) and a beta blocker. (Strength of Evidence = A) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Aldosterone antagonists are not recommended when creatinine is &amp;gt;2.5 mg/dL (or creatinine clearance is &amp;lt;30 mL/min) or serum potassium is &amp;gt;5.0 mmol/L or in conjunction with other potassium-sparing diuretics. (Strength of Evidence = A) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;It is recommended that serum potassium concentration be monitored frequently following initiation or change in an aldosterone antagonist. Monitoring should reflect protocols followed in clinical trials. (Strength of Evidence = A) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In the absence of persistent hypokalemia (&amp;lt;4.0 mmol/L), supplemental potassium is not recommended in patients taking an aldosterone antagonist. (Strength of Evidence = A) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Oral Nitrates and Hydralazine&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;19&quot;&gt;&#xD;&#xA;    &lt;li&gt;A combination of hydralazine and isosorbide dinitrate is recommended as part of standard therapy in addition to beta blockers and ACE inhibitors for African Americans with HF and reduced LVEF.&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;NYHA III or IV HF (Strength of Evidence = A) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;NYHA II HF (Strength of Evidence = B) (See the National Guideline Clearinghouse [NGC] summary of Heart Failure Society of American [HFSA] guideline, &lt;a href=&quot;/content.aspx?id=23911&quot; title=&quot;Guideline #7994&quot;&gt;Management of Heart Failure in Special Populations&lt;/a&gt; &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;A combination of hydralazine and isosorbide dinitrate may be considered in non&amp;ndash;African-American patients with HF and reduced LVEF who remain symptomatic despite optimized standard therapy. (Strength of Evidence = C) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Optimal Use of Multi-Drug Therapy&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;21&quot;&gt;&#xD;&#xA;    &lt;li&gt;Additional pharmacologic therapy should be considered in patients with HF and reduced LVEF who have persistent symptoms or progressive worsening despite optimized therapy with an ACE inhibitor and beta blocker. The choice of specific agent will be influenced by clinical considerations, including renal function status, chronic serum potassium concentration, blood pressure, and volume status. The triple combination of an ACE inhibitor, an ARB, and an aldosterone antagonist is not recommended because of the high risk of hyperkalemia. (Strength of Evidence = C)&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Addition of an ARB. (Strength of Evidence = A) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Addition of an aldosterone antagonist:&#xD;&#xA;        &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;            &lt;li&gt;For severe HF (Strength of Evidence = A) &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;For moderate HF (Strength of Evidence = C) &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;For post-MI HF (Strength of Evidence = A) &lt;/li&gt;&#xD;&#xA;        &lt;/ul&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Addition of the combination of hydralazine/isosorbide dinitrate:&#xD;&#xA;        &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;            &lt;li&gt;For African Americans (Strength of Evidence = A) &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;For others (Strength of Evidence = C) &lt;/li&gt;&#xD;&#xA;        &lt;/ul&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;22&quot;&gt;&#xD;&#xA;    &lt;li&gt;Additional pharmacological therapy should be considered in patients with HF and reduced LVEF &lt;em&gt;who are unable to tolerate a beta blocker&lt;/em&gt; and have persistent symptoms or progressive worsening despite optimized therapy with an ACE inhibitor. The choice of specific agent will be influenced by clinical considerations, including renal function status, chronic serum potassium concentration, blood pressure and volume status. The triple combination of an ACE inhibitor, an ARB, and an aldosterone antagonist is not recommended due to the high risk of hyperkalemia. (Strength of Evidence = C)&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Addition of an ARB. (Strength of Evidence = C) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Addition of an aldosterone antagonist:&#xD;&#xA;        &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;            &lt;li&gt;For severe HF (Strength of Evidence = C) &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;For moderate HF (Strength of Evidence = C) &lt;/li&gt;&#xD;&#xA;        &lt;/ul&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Addition of the combination of hydralazine/isosorbide dinitrate:&#xD;&#xA;        &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;            &lt;li&gt;For African Americans (Strength of Evidence = C) &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;For others (Strength of Evidence = C) &lt;/li&gt;&#xD;&#xA;        &lt;/ul&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Diuretic Therapy&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;23&quot;&gt;&#xD;&#xA;    &lt;li&gt;Diuretic therapy is recommended to restore and maintain normal volume status in patients with clinical evidence of fluid overload, generally manifested by congestive symptoms (orthopnea, edema, and shortness of breath), or signs of elevated filling pressures (jugular venous distention, peripheral edema, pulsatile hepatomegaly, and, less commonly, rales). (Strength of Evidence = A) Loop diuretics rather than thiazide-type diuretics are typically necessary to restore normal volume status in patients with HF. (Strength of Evidence = B) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The initial dose of diuretic may be increased as necessary to relieve congestion. Restoration of normal volume status may require multiple adjustments over many days and occasionally weeks in patients with severe fluid overload evidenced by massive edema or ascites. After a diuretic effect is achieved with short-acting loop diuretics, increasing administration frequency to twice or even 3 times per day will provide more diuresis with less physiologic perturbation than larger single doses. (Strength of Evidence = B)&#xD;&#xA;    &lt;p&gt;Oral torsemide may be considered in patients in whom poor absorption of oral medication or erratic diuretic effect may be present, particularly those with right-sided HF and refractory fluid retention despite high doses of other loop diuretics. (Strength of Evidence = C)&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;Intravenous administration of diuretics may be necessary to relieve congestion. (Strength of Evidence = A)&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;Diuretic refractoriness may represent patient noncompliance, a direct effect of diuretic use on the kidney, or progression of underlying cardiac dysfunction.&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Addition of chlorothiazides or metolazone, once or twice daily, to loop diuretics should be considered in patients with persistent fluid retention despite high-dose loop diuretic therapy. But chronic daily use, especially of metolazone, should be avoided if possible because of the potential for electrolyte shifts and volume depletion. These drugs may be used periodically (every other day or weekly) to optimize fluid management. Metolazone will generally be more potent and much longer-acting in this setting and in patients with chronic renal insufficiency, so administration should be adjusted accordingly. Volume status and electrolytes must be monitored closely when multiple diuretics are used. (Strength of Evidence = C) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Careful observation for the development of side effects, including electrolyte abnormalities, symptomatic hypotension, renal dysfunction, or worsening renal function, is recommended in patients treated with diuretics, especially when used at high doses and in combination. Patients should undergo routine laboratory studies and clinical examination as dictated by their clinical response. (Strength of Evidence = B) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients requiring diuretic therapy to treat fluid retention associated with HF generally require chronic treatment, although often at lower doses than those required initially to achieve diuresis. Decreasing or even discontinuing diuretics may be considered in patients experiencing significant improvement in clinical status and cardiac function or in those who successfully restrict dietary sodium intake. These patients may undergo cautious weaning of diuretic dose and frequency with careful observation for recurrent fluid retention. (Strength of Evidence = C) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;It is recommended that patients and caregivers be given education that will enable them to demonstrate understanding of the early signs of fluid retention and the plan for initial therapy. (Strength of Evidence = C)&#xD;&#xA;    &lt;p&gt;Selected patients may be educated to adjust daily dose of diuretic in response to weight gain from fluid overload (typically short-term weight gain of 2 to 4 lb). (Strength of Evidence = C) (See the NGC summary of the HFSA guideline, &lt;a href=&quot;/content.aspx?id=23902&quot; title=&quot;Guideline #7985&quot;&gt;Nonpharmacologic Management and Health Care Maintenance in Patients With Chronic Heart Failure&lt;/a&gt;).&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Digoxin may be considered to improve symptoms in patients with reduced LVEF (LVEF &amp;le;40%) who have signs or symptoms of HF while receiving standard therapy, including ACE inhibitors and beta blockers:&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;NYHA class II-III (Strength of Evidence = B) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;NYHA class IV (Strength of Evidence = C) &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;It is recommended that the dose of digoxin, which should be based on lean body mass, renal function, and concomitant medications, should be 0.125 mg daily in the majority of patients and the serum digoxin level should be &amp;lt;1.0 ng/mL, generally 0.7 to 0.9 ng/mL. (Strength of Evidence = B) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Digoxin should be considered for achieving adequate control of the ventricular response to atrial fibrillation in patients with HF. (Level of Evidence = B) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;High doses of digoxin (maintenance dose &amp;gt;0.25 mg daily) for the purpose of rate control are not recommended. (Strength of Evidence = C) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Anticoagulation and Antiplatelet Drugs&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;33&quot;&gt;&#xD;&#xA;    &lt;li&gt;Treatment with warfarin (goal international normalized ratio [INR] 2.0 to 3.0) is recommended for all patients with HF and chronic or documented paroxysmal, persistent, or long-standing atrial fibrillation (Strength of Evidence = A) or a history of systemic or pulmonary emboli, including stroke or transient ischemic attack (Strength of Evidence = C), unless contraindicated. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;It is recommended that patients with symptomatic or asymptomatic ischemic cardiomyopathy and documented recent large anterior MI or recent MI with documented LV thrombus be treated with warfarin (goal international normalized ratio 2.0 to 3.0) for the initial 3 months post-MI (Strength of Evidence = B) unless contraindicated.&#xD;&#xA;    &lt;p&gt;Other patients with ischemic or nonischemic cardiomyopathy and LV thrombus should be considered for chronic anticoagulation, depending on the characteristics of the thrombus, such as its size, mobility, and degree of calcification. (Strength of Evidence = C)&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Long-term treatment with an antiplatelet agent, generally aspirin in doses of 75 to 81 mg, is recommended for patients with HF due to ischemic cardiomyopathy, whether or not they are receiving ACE inhibitors. (Strength of Evidence = B)&#xD;&#xA;    &lt;p&gt;Warfarin (goal international normalized ratio 2.0 to 3.0) and clopidogrel (75 mg) also have prevented vascular events in post-MI patients and may be considered as alternatives to aspirin. (Strength of Evidence = B)&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Routine use of aspirin is not recommended in patients with HF without atherosclerotic vascular disease. (Strength of Evidence = C) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Amiodarone Therapy&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;37&quot;&gt;&#xD;&#xA;    &lt;li&gt;Antiarrhythmic agents, including amiodarone, are not recommended for the primary prevention of sudden death in patients with HF. (Strength of Evidence = A) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In patients with HF and an implantable cardioverter defibrillator (ICD), amiodarone may be considered to reduce the frequency of recurrent symptomatic arrhythmias causing ICD shocks. (Strength of Evidence = C) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;It is recommended that when amiodarone therapy is initiated, the potential for interactions with other drugs be reviewed. The maintenance doses of digoxin, warfarin, and some statins should be reduced when amiodarone is initiated and then carefully monitored. Adjustment in doses of these drugs and laboratory assessment of drug activity or serum concentration after initiation of amiodarone is recommended. (Strength of Evidence = A) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Routine use of amiodarone therapy for asymptomatic arrhythmias that are not felt to contribute to HF or ventricular dysfunction is not recommended. (Strength of Evidence = B) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Polyunsaturated Fatty Acids&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;41&quot;&gt;&#xD;&#xA;    &lt;li&gt;n-3 polyunsaturated fatty acids (PUFA) may be considered to reduce mortality in HF patients with NYHA class II-IV symptoms and reduced LVEF. (Strength of Evidence = B) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Definitions&lt;/span&gt;&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Strength of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: Hierarchy of Types of Evidence&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; colspan=&quot;2&quot;&gt;Hierarchy of Types of Evidence&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Level A&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Randomized, Controlled, Clinical Trials&lt;br /&gt;&#xD;&#xA;            May be assigned based on results of a single methodologically rigorous trial&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Level B&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Cohort and Case-Control Studies&lt;br /&gt;&#xD;&#xA;            Post hoc, subgroup analysis, and meta-analysis&lt;br /&gt;&#xD;&#xA;            Prospective observational studies or registries&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Level C&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Expert Opinion&lt;br /&gt;&#xD;&#xA;            Observational studies &amp;ndash; epidemiologic findings&lt;br /&gt;&#xD;&#xA;            Safety reporting from large-scale use in practice&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Strength of Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: Classifying the Strength of the Recommendations&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&quot;Is recommended&quot;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Part of routine care&lt;br /&gt;&#xD;&#xA;            Exceptions to therapy should be minimized. &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&quot;Should be considered&quot;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Majority of patients should receive the intervention.&lt;br /&gt;&#xD;&#xA;            Some discretion in application to individual patients should be allowed.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&quot;May be considered&quot; &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Individualization of therapy is indicated.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&quot;Is not recommended&quot;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Therapeutic intervention should not be used&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None provided&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of supporting evidence is identified and graded for each recommendation (see the &quot;Major Recommendations&quot;).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Improved symptoms and quality of life &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Slowing of the progression or reversing cardiac and peripheral dysfunction &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Reduced mortality and morbidity&lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;All of the pharmacologic agents recommended have potential side effects and/or adverse effects, which are described in the original guideline document.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="430" OrdBy="800" Name="Contraindications"><Field FieldID="144" OrdBy="805" ID="431" Name="Contraindications" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Some interventions carry relative or absolute contraindications. These contraindications vary according to the specific intervention and are described in the recommendations and accompanying text of the original guideline document.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="432" OrdBy="900" Name="Qualifying Statements"><Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;It must be recognized that the evidence supporting recommendations is based largely on population responses that may not always apply to individuals within the population. Therefore, data may support overall benefit of one treatment over another but cannot exclude that some individuals within the population may respond better to the other treatment. Thus, guidelines can best serve as evidence-based recommendations for management, not as mandates for management in every patient. Furthermore, it must be recognized that trial data on which recommendations are based have often been carried out with background therapy not comparable to therapy in current use. Therefore, physician decisions regarding the management of individual patients may not always precisely match the recommendations. A knowledgeable physician who integrates the guidelines with pharmacologic and physiologic insight and knowledge of the individual being treated should provide the best patient management.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The value of a practice guideline is significantly influenced by the scope of its dissemination. The first and second Heart Failure Society of America guidelines were available on the Internet, and thousands of copies were downloaded. The current document will be implemented on the Internet both for file transfer and as a hypertext source of detailed knowledge concerning heart failure.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="117" OrdBy="1015" ID="437" Name="Implementation Tools" Type="picklist-many"><FieldValue Value="Quick Reference Guides/Physician Guides" /><FieldValue Value="Slide Presentation" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Living with Illness" /><FieldValue Value="Staying Healthy" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /><FieldValue Value="Patient-centeredness" /><FieldValue Value="Safety" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Heart Failure Society of America, Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA, Givertz MM, Katz SD, Klapholz M, Moser DK, Rogers JG, Starling RC, Stevenson WG, Tang WH, Teerlink JR, Walsh MN. Heart failure in patients with reduced ejection fraction: HFSA 2010 comprehensive heart failure practice guideline. J Card Fail. 2010 Jun;16(6):e73-97. [174 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="1999 (revised 2010 Jun)" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="Heart Failure Society of America, Inc - Disease Specific Society" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Heart Failure Society of America, Inc&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Heart Failure Society of America Guideline Committee&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Guideline Committee Members&lt;/em&gt;: JoAnn Lindenfeld, MD (&lt;em&gt;Chair&lt;/em&gt;); Nancy M. Albert, RN, PhD; John P. Boehmer, MD; Sean P. Collins, MD, MSc; Justin A. Ezekowitz, MBBCh; Michael M. Givertz, MD; Stuart D. Katz, MD; Marc Klapholz, MD; Debra K. Moser, RN, DNSc; Joseph G. Rogers, MD; Randall C. Starling, MD, MPH; William G. Stevenson, MD; W.H. Wilson Tang, MD; John R. Teerlink, MD; Mary N. Walsh, MD&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Executive Council&lt;/em&gt;: Douglas L. Mann, MD, President; Inder S. Anand, MD; J. Malcolm O. Arnold, MD; John C. Burnett, Jr., MD; John Chin, MD; Jay N. Cohn, MD; Thomas Force, MD; Barry H. Greenberg, MD; Steven R. Houser, PhD; Mariell L. Jessup, MD; Barry M. Massie, MD; Mandeep R. Mehra, MD; Mariann R. Piano, RN, PhD; Clyde W. Yancy, MD; Michael R. Zile, MD&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Committee members and reviewers from the Executive Council received no direct financial support from the Heart Failure Society of America (HFSA) or any other source for the development of the guideline. Support was provided by the HFSA administrative staff, but the writing of the document was performed on a volunteer basis primarily by the Committee. Financial relationships that might represent conflicts of interest were collected annually from all members of the Guideline Committee and the Executive Council. Current relationships are shown in Appendix C of the &quot;2010 HFSA Guideline Executive Summary&quot; companion document (see the &quot;Availability of Companion Documents&quot; field).&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: Heart Failure Society of America. Heart failure in patients with left ventricular systolic dysfunction. J Card Fail 2006 Feb;12(1):e38-57.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Available from the &lt;a href=&quot;http://www.heartfailureguideline.org/&quot; title=&quot;HFSA Web site&quot;&gt;Heart Failure Society of America, Inc. Web site&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Print copies: Available from the Heart Failure Society of America, Inc., Court International - Suite 240 S, 2550 University Avenue West, Saint Paul, Minnesota 55114; Phone: (651) 642-1633&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following are available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Heart Failure Society of America. Executive summary: The 2010 HFSA comprehensive heart failure practice guideline. J Card Fail 2010 Jun. Electronic copies: Available from the &lt;a href=&quot;http://www.onlinejcf.com/article/S1071-9164%2810%2900174-0/fulltext&quot; title=&quot;Journal of Cardiac Failure Web site&quot;&gt;Journal of Cardiac Failure Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Heart Failure Society of America. Development and implementation of a comprehensive heart failure practice guideline. J Card Fail 2010 Jun;16(6):e3-6. Electronic copies: Available from the &lt;a href=&quot;http://www.onlinejcf.com/article/S1071-9164%2810%2900174-0/fulltext&quot; title=&quot;Journal of Cardiac Failure Web site&quot;&gt;Journal of Cardiac Failure Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Heart Failure Society of America. Conceptualization and working definition of heart failure. J Card Fail 2010 Jun;16(6):e34-7. Electronic copies: Available from the &lt;a href=&quot;http://www.onlinejcf.com/article/S1071-9164%2810%2900174-0/fulltext&quot; title=&quot;Journal of Cardiac Failure Web site&quot;&gt;Journal of Cardiac Failure Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;PowerPoint slides. HFSA 2010 comprehensive heart failure guideline. Electronic copies: Available from the &lt;a href=&quot;http://www.heartfailureguideline.org/slide_sets_all_recommendations/42&quot; title=&quot;HFSA Web site&quot;&gt;Heart Failure Society of America, Inc. Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Print copies: Available from the Heart Failure Society of America, Inc., Court International - Suite 240 South, 2550 University Avenue West, Saint Paul, Minnesota 55114; Phone: (651) 642-1633&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI on July 31, 2006. The information was verified by the guideline developer on August 10, 2006. This summary was updated by ECRI on March 6, 2007 following the U.S. Food and Drug Administration (FDA) advisory on Coumadin (warfarin sodium). This summary was updated by ECRI Institute on September 7, 2007 following the revised U.S. Food and Drug Administration (FDA) advisory on Coumadin (warfarin). This summary was updated by ECRI Institute on January 4, 2010 following the U.S. Food and Drug Administration advisory on Plavix (Clopidogrel). This summary was updated by ECRI Institute on May 17, 2010 following the U.S. Food and Drug Administration advisory on Plavix (clopidogrel). This NGC summary was updated by ECRI Institute on October 14, 2010. The updated information was verified by the guideline developer on November 23, 2010.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions. Please direct inquiries to &lt;a href=&quot;mailto:info@hfsa.org&quot;&gt;info@hfsa.org&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
